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Abstract Phosphodiesterase 3B (PDE3B) gene expression is
generally reduced in large adipocytes of obese, insulin-resistant
mice. This reduced gene expression is restored by peroxisome
proliferator-activated receptor (PPAR) Q ligands accompanied
by a reduced fat cell size. To determine whether PDE3B gene
expression is regulated by PPARQ itself, we analyzed lean
PPARQ (+/3) mice with adipocyte size comparable to control
PPARQ (+/+) mice. In adipocytes of PPARQ (+/3) mice,
PDE3B mRNA and protein were both reduced to 63% of
wild-type levels. Basal PDE activity tended to be decreased to
70% of wild-type levels, and, similarly, insulin-induced PDE
activity was signi¢cantly decreased to 70%. Thus, PPARQ is
required for PDE3B gene expression independent of adipocyte
size.
/ 2003 Published by Elsevier Science B.V. on behalf of the
Federation of European Biochemical Societies.
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1. Introduction
Phosphodiesterase (PDE) 3B is the major isoform of PDE
in adipocytes [1]. Insulin mediates antilipolytic action via the
phosphorylation and activation of PDE3B. The activation of
PDE3B results in decreased intracellular cAMP levels, which
leads to a reduction in cAMP-dependent protein kinase A
activity. This subsequently leads to the inactivation of hor-
mone-sensitive lipase, resulting in a decreased hydrolysis of
stored triglycerides, and a reduced release of free fatty acids
(FFA) from adipocytes [2,3].
Type 2 diabetes mellitus is characterized by insulin resis-
tance in insulin target tissues such as adipose tissue, skeletal
muscle, and liver [4]. Reduced insulin sensitivity in adipose
tissues might represent an event prior to overt insulin resis-
tance in skeletal muscle and liver [5,6]. When the antilipolytic
action of insulin is impaired, the release of FFA from adipo-
cytes is increased. It is a well-known fact that the elevation of
serum FFA causes insulin resistance in skeletal muscle and
liver, as well as adipose tissue [7^9].
The reduced PDE3B gene expression in adipocytes could
result in an increased FFA output leading to whole body
insulin resistance. In fact, PDE3B (3/3) mice show insulin
resistance with an elevated lipolytic capacity [10]. We previ-
ously showed that PDE3B gene expression is reduced in the
large adipocytes of obese insulin-resistant KKAy mice and db/
db mice [11^13]. PDE3B mRNA is also reduced in obese
insulin-resistant cp/cp rats [14]. Therefore, a reduced PDE3B
gene expression in large adipocytes appears to be a general
phenomenon associated with the obese insulin-resistant state.
We previously reported that peroxisome proliferator-acti-
vated receptor (PPAR) Q ligands, thiazolidinediones, increase
PDE3B gene expression in adipose tissues of obese insulin-
resistant KKAy or db/db mice [11,13]. It has been reported
that thiazolidinediones cause an increase in the number of
small adipocytes, probably by inducing adipocyte di¡erentia-
tion in obese insulin-resistant Zucker rats [15,16]. We also
reported that PDE3B mRNA and its promoter activity are
induced on adipocyte di¡erentiation in 3T3-L1 cells [17].
Therefore, PPARQ might enhance PDE3B gene expression di-
rectly by activating its gene transcription or indirectly by re-
ducing the fat cell size.
PPARQ is known to be a master regulator of adipocyte
di¡erentiation [18]. In fact, the ability of embryonic ¢bro-
blasts from PPARQ (+/3) mice to di¡erentiate into adipocytes
is approximately 50% lower than that of PPARQ (+/+) mice
[19]. Since the numbers of epididymal fat cells do not change
irrespective of fat mass in these mice under a standard, high
carbohydrate, or high fat diet [19], fat mass should correlate
with fat cell size.
In view of this, we initiated a study of PDE3B gene expres-
sion in epididymal fat tissues of lean PPARQ (+/3) mice under
standard diet conditions. The body weight as well as epididy-
mal fat pad weight of PPARQ (+/3) mice were comparable to
those of PPARQ (+/+) mice, which enabled us to investigate
the direct e¡ect of PPARQ independent of the e¡ect of fat cell
size. Steady-state mRNA and protein of PDE3B were reduced
in adipocytes of PPARQ (+/3) mice. Basal PDE activity
tended to be decreased to 70% of wild-type levels, and, sim-
ilarly, insulin-induced PDE activity was signi¢cantly de-
creased to 70%. The fold induction by insulin was not af-
fected.
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2. Materials and methods
2.1. Animals and tissue preparation
Male PPARQ (+/3) mice (C57BL/6J, CBA, and ICR hybrid back-
ground) were generated as described previously [19]. These mice had
been backcrossed with C57BL/6J mice more than four times. PPARQ
(+/+) wild-type littermates were used as controls. These mice were
caged in groups of ¢ve and were provided with food and water ad
libitum, and were used for experiments at an age of 10^14 weeks. The
mice were killed by rapid decapitation under light diethyl ether inha-
lation, and epididymal fat tissues were rapidly removed. For the
RNase protection assay, the tissues were homogenized and stored,
as described previously [11]. For an assay for membrane-bound
PDE activity and Western blotting, isolated adipocytes were prepared
from fresh fat tissues by the collagenase method, as described previ-
ously [20]. Blood samples were also collected at the time of death.
Serum glucose, FFA, triglycerides, and insulin were determined as
described previously [11]. All experimental procedures were approved
by the Animal Experimentation Committee of Ehime University
School of Medicine.
2.2. RNase protection assay (RPA)
Total RNA was isolated from adipose tissue homogenates, and the
RPA was performed as described previously [11]. Since the protected
PDE3B and L-actin RNAs are of di¡erent sizes (395 and 250 nt,
respectively), both RNA species could be quantitated in a single
RNA sample. We con¢rmed that L-actin mRNA could be used to
correct the PDE3B mRNA in each sample, as has been shown pre-
viously [11].
2.3. Western blotting
PDE3B protein levels in isolated adipocytes were assessed by West-
ern blotting as described previously using an anti-rat PDE3B poly-
clonal antibody raised in rabbits against the NH2-terminal peptide
(amino acid residues 1^17) [11].
2.4. Membrane-bound PDE catalytic activity
Membrane-bound PDE activity was assayed as described earlier
[21,22]. Brie£y, isolated adipocytes, which were incubated with or
without 4 nmol/l insulin, were homogenized with bu¡er A (10 mM
TES (N-tris-[hydroxymethyl]-methyl-2-aminoethanesulfonic acid), pH
7.0 containing 0.25 M sucrose). The membrane-bound fraction was
then suspended in bu¡er A, pH 7.5, and PDE activity was then de-
termined.
2.5. Statistical analysis
An unpaired Student’s t-test was used for all the experiments, and
results are expressed as the meanQS.E.M. from at least four mice.
3. Results
3.1. Body weight, epididymal fat pad weight, and serum insulin,
glucose, FFA and triglycerides levels in PPARQ (+/3)
mice
We ¢rst compared the body weight, epididymal fat pad
weight, serum insulin, glucose, FFA and triglyceride concen-
trations of the PPARQ (+/3) mice to those of control PPARQ
(+/+) mice under standard diet conditions (Table 1). The body
weight and epididymal fat pad weight of the PPARQ (+/3)
mice were comparable to those of PPARQ (+/+) mice. Since
the numbers of epididymal fat cells were not di¡erent between
PPARQ (+/3) and PPARQ (+/+) mice [19], the size of the fat
cells of PPARQ (+/3) mice was considered to be comparable
to that of PPARQ (+/+) mice. No signi¢cant di¡erences in the
other parameters were detected between the PPARQ (+/3) and
PPARQ (+/+) mice.
3.2. PDE3B mRNA in adipose tissues of PPARQ (+/3) mice
To determine whether PDE3B gene expression is directly
regulated by PPARQ, the PDE3B mRNA in adipose tissues
of PPARQ (+/3) mice was ¢rst compared to that of control
PPARQ (+/+) mice using RPA (Fig. 1). The PDE3B mRNA in
the PPARQ (+/3) mice was decreased to 63% of PPARQ (+/+)
mice (PPARQ (+/+) 100Q 20 vs. PPARQ (+/3) 63Q 16%, n=5,
P6 0.01). Since we have consistently observed that PDE3B
mRNA in adipose tissues correlates with PDE3B protein in
adipocytes [11^13,24], we assume that changes in PDE3B
mRNA levels in adipose tissue re£ect alterations in adipo-
cytes.
3.3. PDE3B protein in adipocytes of PPARQ (+/3) mice
To examine whether the decreased PDE3B mRNA in the
adipose tissues of PPARQ (+/3) mice is related to PDE3B
protein in their isolated adipocytes, we next assessed the
steady-state PDE3B protein level by Western blotting (Fig.
2). The speci¢city of our antibody was veri¢ed by an absorp-
tion test using a peptide to which the antibody had been
Table 1
Total body and fat pad weight, and serum insulin, glucose, FFA, and triglyceride levels in PPARQ (+/3) and control PPARQ (+/+) mice
Experimental group n Body weight
(g)
Epididymal fat
pad weight (g)
Insulin
(ng/ml)
Glucose
(mg/dl)
FFA
(mEq/l)
Triglycerides
(mg/dl)
Control PPARQ
(+/+) mice
4 40.5Q 1.2 0.76Q 0.16 3.04Q 0.44 245.8Q 1.9 1.68Q 0.26 194Q 41
PPARQ (+/3) mice 10 41.4Q 1.1 0.73Q 0.09 3.41Q 0.62 243.5Q 4.9 1.84Q 0.13 199Q 19
Data are meanQS.E.M. No signi¢cant di¡erence (P6 0.05) between control PPARQ (+/+) and PPARQ (+/3) mice was detected.
Fig. 1. PDE3B mRNA in adipose tissues of PPARQ (+/3) mice.
PDE3B mRNA was measured by RPA using epididymal fat tissues
from 10^14 week old PPARQ (+/3) and control PPARQ (+/+) mice
as described in Section 2. PDE3B mRNA is expressed as the inten-
sity of the protected PDE3B band corrected by that of the protected
L-actin band in each lane. The mean value in the control mice is
then de¢ned as 100% and the relative value is shown as the mean-
s Q S.E.M. (%). **P6 0.01, signi¢cant di¡erence compared to con-
trol PPARQ (+/+) mice (n=5).
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raised, as described previously [11]. PDE3B protein in adipo-
cytes of the PPARQ (+/3) mice was decreased to 63% of
PPARQ (+/+) mice (PPARQ (+/+) 100Q 11 vs. PPARQ (+/3)
63Q 4%, n=4, P6 0.05) (Fig. 2). Thus, PDE3B protein levels
were decreased in adipocytes of PPARQ (+/3) mice, which
correlates with the levels of PDE3B mRNA in adipose tissues.
3.4. Basal and insulin-induced membrane-bound PDE activities
in adipocytes of PPARQ (+/3) mice
To examine whether the heterozygous de¢ciency of PPARQ
a¡ects the insulin signaling pathway leading to PDE3B acti-
vation, basal and insulin-induced membrane-bound PDE
(mainly PDE3B) activities were measured (Fig. 3). In epididy-
mal adipocytes of PPARQ (+/3) mice, basal membrane-bound
PDE activity was slightly reduced to 74% of PPARQ (+/+)
mice, although the di¡erence did not quite reach signi¢cance
(PPARQ (+/+) 40.0Q 3.0 pmol/mg/min vs. PPARQ (+/3)
29.6 Q 4.3 pmol/mg/min, n=5, P=0.08). This tendency corre-
lates with PDE3B mRNA and protein levels. Insulin-induced
membrane-bound PDE activity was reduced to 70% of PPARQ
(+/+) mice (PPARQ (+/+) 83.0 Q 7.1 pmol/mg/min vs. PPARQ
(+/3) 57.9 Q 6.0 pmol/mg/min, n=4, P6 0.05). The fold in-
duction by insulin (insulin-induced/basal activity) was not af-
fected in the PPARQ (+/3) mice (PPARQ (+/+) 2.2 Q 0.1-fold
vs. PPARQ (+/3) 2.1 Q 0.3-fold, n=4, P=0.71). Therefore, in
adipocytes of PPARQ (+/3) mice, PDE3B gene expression was
reduced, whereas the insulin signaling pathway leading to
PDE3B activation was not probably a¡ected.
4. Discussion
The data herein show that PDE3B mRNA and the corre-
sponding protein levels were both reduced in adipocytes of
PPARQ (+/3) mice under standard diet conditions. Although
not signi¢cant, the basal PDE3B activity showed a consistent
decrease. Insulin-induced PDE3B activities were also reduced,
whereas the fold induction by insulin (insulin-induced/basal)
was not a¡ected.
PDE3B gene expression was decreased in adipocytes of lean
PPARQ (+/3) mice. Since the size of fat cells of PPARQ (+/3)
mice is comparable to that of PPARQ (+/+) mice, PPARQ may
induce PDE3B gene expression, at least in part, independent
of fat cell size. PPARQ is known to regulate gene transcription
by binding to its DNA elements or by interacting with other
factors without directly binding to DNA [18,23].
PDE3B gene expression appears to be regulated by at least
two factors, fat cell size and PPARQ. We reported that
PDE3B gene expression is reduced in large adipocytes of
obese insulin-resistant KKAy or db/db mice [12,13], whereas
this gene expression is enhanced in small adipocytes of lean
insulin-resistant IRS-1 (3/3) mice [24]. The present data sug-
gest that PPARQ itself is also required for inducing PDE3B
gene expression in adipocytes.
No signi¢cant di¡erences in serum FFA and triglyceride
levels were found between PPARQ (+/3) mice and PPARQ
(+/+) mice. In adipocytes of PPARQ (+/3) mice, PDE3B
mRNA and protein were both reduced to 63% of PPARQ
(+/+) mice. Basal PDE activity tended to be decreased to
70% of PPARQ (+/+) mice, and, similarly, insulin-induced
PDE activity was signi¢cantly decreased to 70%. This modest
Fig. 2. PDE3B protein in adipocytes of PPARQ (+/3) mice. Western
blotting was carried out using an anti-PDE3B antibody raised
against the N-terminal peptide (residues 1^17) of rat PDE3B as de-
scribed in Section 2. All mice were 10^14 weeks of age. The mean
value of the PDE3B protein intensity of the PPARQ (+/3) mice is
de¢ned as 100% and the relative value is shown as the meanQ
S.E.M. (%). *P6 0.05, signi¢cant di¡erence compared to control
PPARQ (+/+) mice (n=4).
Fig. 3. Basal and insulin-induced membrane-bound PDE activities
in adipocytes of PPARQ (+/3) mice. The basal and insulin-induced
activities of the membrane-bound PDE were determined in epididy-
mal adipocytes from 10^14 week old PPARQ (+/3) and control
PPARQ (+/+) mice as described in Section 2. Columns represent the
meanQS.E.M. of PDE catalytic activity (pmol/mg/min). Numbers
indicate the insulin inducibility of PDE activity (insulin-treated/basal
activities, fold induction). *P6 0.05, signi¢cant di¡erence compared
to basal activity of PPARQ (+/3) mice (n=4).
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reduction of basal and insulin-induced PDE3B activity may
not be su⁄cient to cause signi¢cant changes in serum FFA
and triglyceride levels in PPARQ (+/3) mice. Una¡ected levels
of serum FFA and triglycerides have also been reported by
another group [25].
The fold induction of PDE3B activity by insulin was not
a¡ected in adipocytes of PPARQ (+/3) mice. The reduction in
the basal PDE3B activity appears to be comparable with that
in the insulin-induced PDE3B activity. These reduced PDE3B
activities could result from reduced PDE3B protein levels
whereas molecules involved in the insulin signaling pathway
leading to PDE3B activation do not appear to be a¡ected in
adipocytes of these mice.
In PPARQ (+/3) mice, PDE3B gene expression and insulin-
induced PDE3B activity were reduced, which could result in a
reduced capacity for triglyceride storage in these adipocytes.
In fact, in the case of a high fat diet, PPARQ (+/3) mice
remain lean and insulin-sensitive, whereas control PPARQ
(+/+) mice become obese and insulin-resistant [19]. This phe-
nomenon appears to be paradoxical since a PPARQ ligand has
an insulin sensitizing e¡ect. It has been proposed that the
relation between insulin sensitivity and the amount of PPARQ
¢ts into an inverted U shape [26]. An appropriate amount of
PPARQ, probably 50% of the normal amount in these mice,
provides better insulin sensitivity under conditions of a high
fat diet.
In summary, PDE3B gene expression was decreased in adi-
pocytes of PPARQ (+/3) mice compared to control PPARQ
(+/+) mice. The size of fat cells of PPARQ (+/3) mice is
comparable to that of PPARQ (+/+) mice, suggesting that
PPARQ itself may be required for inducing PDE3B gene ex-
pression independent of fat cell size. The issues of how
PDE3B gene expression is regulated by PPARQ and how a
reduced PDE3B gene expression protects against obesity in
PPARQ (+/3) mice under a high fat diet remain unclear. Fur-
ther experiments will be required to clarify these points.
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